|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Synthesis and Antitumor Activity Evaluation of γ-Monofluorinated and γγy-Difluorinated Goniothalamin Analogues显示文摘一系列小说, -difluorinated Goniothalamin 类似物 4a4i 和 6a6i 被综合。关键步通过脂肪分解酵素 AK 包括了邻近 gem-difluoromethylene 组的 C-5 stereocenter 的构造催化运动分辨率,经由联合的 Stille 的芳基组的介绍,和由 1,5-oxidative 的 lactonization 环合。这些, -difluorinated Goniothalamin 类似物 4a4i 和他们的 enantiomers 6a6i,和几相应 -monofluorinated Goniothalamin,类似物生物学上与四根不同癌症房间线被作比较。复合 7h 在 micromolar 范围作为父母(R)-Goniothalamin 显示出将近相等的力量。在在 antitumor 活动的 fluoromethylene 和 gem-difluoromethylene 之间的不同氟的符号效果通过生物鉴定数据的分析被讨论。 | Yi Yang Zhenjun Yang Chunru Cheng Fengling Qing | 2013 | Chinese Journal of Chemistry2013，31，6： | 2 |
| 2 | Sustainable agricultural development inChina显示文摘 | Cheng Xu Han Chunru Donald C Taylor | | World Development0，220，8： | 1 |
| 3 | World Development 显示文摘 | Cheng xu Han Chunru Donald C et aL Sustainable agricultural development is china | 1992 | 20(8):1127-11441992，20，8： | 1 |
| 4 | Rhodanine flanked indacenodithiophene as non-fullerene acceptor for efficient polymer solar cells显示文摘A fused-ring electron acceptor IDT-2BR1 based on indacenodithiophene core with hexyl side-chains flanked by benzothiadiazole rhodanine was designed and synthesized.In comparison with its counterpart with hexylphenyl side-chains(IDT-2BR),IDT-2BR1exhibits higher highest occupied molecular orbital(HOMO)energy but similar lowest unoccupied molecular orbital(LUMO)energy(IDT-2BR1:HOMO=-5.37eV,LUMO=-3.67eV;IDT-2BR:HOMO=-5.52eV,LUMO=-3.69eV),red-shifted absorption and narrower bandgap.IDT-2BR1 has higher electron mobility(2.2×10^(-3)cm^2 V^(-1)s^(-1))than IDT-2BR(3.4×10^(-4)cm^2 V^(-1)s^(-1))due to the reduced steric hindrance and ordered molecular packing.Fullerene-free organic solar cells based on PTB7-Th:IDT-2BRl yield power conversion efficiencies up to 8.7%,higher than that of PTB7-Th:IDT-2BR(7.7%),with a high open circuit voltage of0.95 V and good device stability. | Boyu Jia Yao Wu Fuwen Zhao Cenqi Yan Siya Zhu Pei Cheng Jiangquan Mai Tsz-Ki Lau Xinhui Lu Chun-Jen Su Chunru Wang Xiaowei Zhan | 2017 | Science China Chemistry2017，60，2： | 0 |
| 5 | GRK2 mediated degradation of SAV1 initiates hyperplasia of fibroblast-like synoviocytes in rheumatoid arthritis显示文摘Hyperplasia and migration of fibroblast-like synoviocytes(FLSs)are the key drivers in the pathogenesis of rheumatoid arthritis(RA)and joint destruction.Abundant Yes-associated protein(YAP),which is a powerful transcription co-activator for proliferative genes,was observed in the nucleus of inflammatory FLSs with unknown upstream mechanisms.Using Gene Expression Omnibus database analysis,it was found that Salvador homolog-1(SAV1),the pivotal negative regulator of the Hippo-YAP pathway,was slightly downregulated in RA synovium.However,SAV1 protein expression is extremely reduced.Subsequently,it was revealed that SAV1 is phosphorylated,ubiquitinated,and degraded by interacting with an important serine-threonine kinase,G protein-coupled receptor(GPCR)kinase 2(GRK2),which was predominately upregulated by GPCR activation induced by ligands such as prostaglandin E2(PGE2)in RA.This process further contributes to the decreased phosphorylation,nuclear translocation,and transcriptional potency of YAP,and leads to aberrant FLSs proliferation.Genetic depletion of GRK2 or inhibition of GRK2 by paroxetine rescued SAV1 expression and restored YAP phosphorylation and finally inhibited RA FLSs proliferation and migration.Similarly,paroxetine treatment effectively reduced the abnormal proliferation of FLSs in a rat model of collagen-induced arthritis which was accompanied by a significant improvement in clinical manifestations.Collectively,these results elucidate the significance of GRK2 regulation of Hippo-YAP signaling in FLSs proliferation and migration and the potential application of GRK2 inhibition in the treatment of FLSs-driven joint destruction in RA. | Paipai Guo Ji Jiang Rui Chu Feng He Mingli Ge Ruhong Fang Qiuyun Guan Huijuan Cheng Chunru Jiang Tiantian Su Zhenduo Zhu Hao Liu Wei Wei Shihao Zhang Qingtong Wang | 2024 | Acta Pharmaceutica Sinica B2024，14，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员